SCHEMBL7997218

SCHEMBL7997218

CC(C)=NN=C(N)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL7493271 0.85 BLM (0.50)
SCHEMBL211089 0.78
SCHEMBL21989218 0.77
Hydrochloric Acid SCHEMBL7809058 0.74 CA1 (0.31)
SCHEMBL19063125 0.72
SCHEMBL24377282 0.67 FURIN (0.39)
SCHEMBL12217939 0.67 ALDH1A1 (0.39)
SCHEMBL12240509 0.67
Acetone SCHEMBL1253506 0.67 LMNA (0.55)
Mitoguazone SCHEMBL11892949 0.64 HRH4 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2665471-B1 CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG PATHOLOGICA LLC (US) 2017-12-27 EP disclosed
US-20110213021-A1 COMPOSITIONS AND METHODS FOR TREATING NOS-ASSOCIATED DISEASES INDIGENE PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110213021-A1 COMPOSITIONS AND METHODS FOR TREATING NOS-ASSOCIATED DISEASES INDIGENE PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
EP-2174938-A1 Quinoline derivatives for modulating DNA methylation SuperGen, Inc. (US) 2010-04-14 EP disclosed
WO-2009111037-A2 COMPOSITIONS AND METHODS FOR TREATING NOS-ASSOCIATED DISEASES INDIGENE PHARMACEUTICALS INC. (US) 2009-09-11 WO disclosed
WO-2009049132-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION SUPERGEN, INC. (US) 2009-04-16 WO disclosed
US-5422360-A Hydrazonoimidazolidin-4-one derivatives; treatment of diabetes and aging disorders OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-06-06 US disclosed
EP-0531812-A1 Maillard reaction inhibitor, process for producing it, composition containing it and the use thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-03-17 EP disclosed